Company profile
4Front Ventures Corp.
OTC: FFNTF · Healthcare · Drug Manufacturers - Specialty & Generic
#364 of 1,418 Healthcare companies by revenue32nd-percentile growth
EA Score
——FH —DQ 19GM —SS 45
v0.1 · 25/100 weight · pillars only
↑ workforce scale, 3-yr revenue growth · ↓ disclosure history, market scale
Methodology →Revenue TTM
$75.5M
Rev growth YoY (TTM)
-34.7%
Net income (FY)
-$91.6M
Employees
374
as of 2026-08-29
Market cap
$12.5k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$86.1M$86.1M2023
Net income-$91.6M-$91.6M2023
Operating income-$20.8M-$20.8M2023
Total assets$264.0M$264.0M2023
Liabilities$315.3M$315.3M2023
Equity-$51.5M-$51.5M2023
Revenue trend
FY2020 – FY2023 · USD
FY20
FY20
FY21
FY23
FY23
Revenue by segment
Filed disclosures · FY2023
By product
T H C Cannabis99%
C B D Wellness1%
By geography
Not disclosed.
The read
What is 4Front Ventures Corp.’s revenue?
4Front Ventures Corp. booked $86.1M in FY2023 revenue, contracting 10% year over year — slower than 68% of Healthcare companies we track, at a -106.4% net margin.
Peers · Healthcare
Cytokinetics, Incorporated59CFluent Corp.45DHarvard Bioscience, Inc.58CStandard BioTools Inc.61CDelcath Systems, Inc.72B4D Molecular Therapeutics, Inc.58CNeighbors
Maricopa →Key facts
CEOAndrew Fisher Thut
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPhoenix, AZ
ExchangeOTC: FFNTF
Employees374
IPO date2018-03-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.